Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 25, Issue , 2014, Pages iii40-iii48

  Bellmunt, J ^a,b   Orsola, A ^c   Leow, J J ^a,b   Wiegel, T ^d   De Santis, M ^e   Horwich, A ^f  

^a HOSPITAL DEL MAR   (Spain)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e KAISER FRANZ JOSEF HOSPITAL   (Austria)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOGEN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOMYCIN; NICOTINAMIDE; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; VINBLASTINE; VINFLUNINE;

ACUTE TOXICITY; ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER STAGING; CHEMORADIOTHERAPY; CYSTECTOMY; CYSTOSCOPY; DISEASE COURSE; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; META ANALYSIS (TOPIC); MONOTHERAPY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; ORGAN PRESERVATION; OVERALL SURVIVAL; PALLIATIVE THERAPY; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; TRANSURETHRAL RESECTION; HEALTH CARE PLANNING; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; STANDARDS; URINARY BLADDER NEOPLASMS;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASM STAGING; PROGNOSIS; SOCIETIES, MEDICAL; URINARY BLADDER NEOPLASMS;

EID: 84910051486     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu223     Document Type: Article

References (47)

1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr (18 February 2014, date last accessed).
2. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/ International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-1448.
3. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press 2004.
4. Amin MB, McKenney JK, Paner GP et al. ICUD-EAU International Consultation on Bladder Cancer 2012: pathology. Eur Urol 2013; 63: 16-35.
5. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-3181.
6. Witjes JA, Compérat E, Cowan NC et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 Guidelines. Eur Urol 2014; 65: 778-792.
7. Edge SB, Byrd DR, Compton CC (eds), AJCC Cancer Staging Handbook, 7th edition. New York, NY: Springer 2010.
8. Stimson CJ, Cookson MS, Barocas DA et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol 2010; 183: 1732-1737.
9. Babjuk M, Burger M, Zigeuner R et al. EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013; 64: 639-653.
10. Gakis G, Efstathiou J, Lerner SP et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscleinvasive urothelial carcinoma of the bladder. Eur Urol 2013; 63: 45-57.
11. Stimson CJ, Chang SS, Barocas DA et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol 2010; 184: 1296-1300.
12. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 189-199; discussion 199-201.
13. Leow JJ, Martin-Doyle W, Rajagopal PS et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 2014; 66: 42-54.
14. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006; 2: CD006018.
15. Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901-2907.
16. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010; 28: 4912-4918.
17. James ND, Hussain SA, Hall E et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366: 1477-1488.
18. Rödel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006; 24: 5536-5544.
19. Rödel C, Grabenbauer GG, Kühn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 3061-3071.
20. Shipley WU, Zietman AL, Kaufman DS et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates-the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 2005; 15: 36-41.
21. Weiss C, Wolze C, Engehausen DG et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006; 24: 2318-2324.
22. Milosevic M, Gospodarowicz M, Zietman A et al. Radiotherapy for bladder cancer. Urology 2007; 69: 80-92.
23. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608.
24. Loehrer PJ, Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10: 1066-1073.
25. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
26. Milowsky MI, Nanus DM, Maluf FC et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2009; 27: 4062-4067.
27. Galsky MD, Iasonos A, Mironov S et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 2007; 109: 549-555.
28. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30: 1107-1113.
29. Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22: 220-228.
30. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-1422.
31. Sternberg CN, de Mulder P, Schornagel JH et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42: 50-54.
32. De Santis M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199.
33. Bellmunt J, Maroto P, Mellado B et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. ASCO Genitourinary Cancers Symposium 2008; abstract 291.
34. Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850-1855.
35. Bellmunt J, Théodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461.
36. Kamat AM, Hegarty PK, Gee JR et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 2013; 63: 4-15.
37. Fernandez-Gomez J, Madero R, Solsona E et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol 2011; 60: 423-430.
38. Xylinas E, Kent M, Kluth L et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013; 109: 1460-1466.
39. Fernandez-Gomez J, Madero R, Solsona E et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model. J Urol 2009; 182: 2195-2203.
40. Iyer G, Al-Ahmadie H, Schultz N et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013; 31: 3133-3140.
41. Al-Ahmadie HA, Iyer G, Janakiraman M et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol 2011; 224: 270-279.
42. Taylor BS, Barretina J, Socci ND et al. Functional copy-number alterations in cancer. PLoS One 2008; 3: e3179.
43. Gui Y, Guo G, Huang Y et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011; 43: 875-878.
44. Solomon DA, Kim JS, Bondaruk J et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013; 45: 1428-1430.
45. Iyer G, Hanrahan AJ, Milowsky MI et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.
46. Ross JS, Wang K, Al-Rohil RN et al. Advanced urothelial carcinoma: nextgeneration sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2014; 27: 271-280.
47. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.